Programme
Programme
Programme
ECNM 2025 Annual Meeting - Programme
ECNM 2025 Annual Meeting - Programme
Day 1, Thursday 18
Day 1, Thursday 18
Day 1, Thursday 18
September 2025
September 2025
September 2025
12:00
Registration opens
12:00
Registration opens
12:00
Registration opens
12:30–12:40
Welcome
Deepti Radia & Clive Grattan
12:30–12:40
Welcome
Deepti Radia & Clive Grattan
12:30–12:40
Welcome
Deepti Radia & Clive Grattan
12:40–13:00
Welcome and introduction
• Status of the ECNM • Presentation of Researcher of the Year award
Peter Valent & Massimo Triggiani
12:40–13:00
Welcome and introduction
• Status of the ECNM • Presentation of Researcher of the Year award
Peter Valent & Massimo Triggiani
12:40–13:00
Welcome and introduction
• Status of the ECNM • Presentation of Researcher of the Year award
Peter Valent & Massimo Triggiani
13:00–13:40
Utility and application of KIT mutations and other molecular markers in mast cell neoplasms
Michel Arock
13:00–13:40
Utility and application of KIT mutations and other molecular markers in mast cell neoplasms
Michel Arock
13:00–13:40
Utility and application of KIT mutations and other molecular markers in mast cell neoplasms
Michel Arock
13:40–14:00
Afternoon coffee break
13:40–14:00
Afternoon coffee break
13:40–14:00
Afternoon coffee break
14:00–15:00
SESSION 1: Updates in pathology and classification
• Harmonisation of the EU/US, ICC and WHO classificationof mastocytosis • Application of ICC and WHO criteria by the pathologist • Histopathological and phenotypic changes of mast cellsduring TKI therapy • Rare cases and histopathological patterns in SM-AHN
Chaired by Wolfgang R Sperr & Karl Sotlar Peter Valent Karl Sotlar Tracy George Hans Peter Horny
14:00–15:00
SESSION 1: Updates in pathology and classification
• Harmonisation of the EU/US, ICC and WHO classificationof mastocytosis • Application of ICC and WHO criteria by the pathologist • Histopathological and phenotypic changes of mast cellsduring TKI therapy • Rare cases and histopathological patterns in SM-AHN
Chaired by Wolfgang R Sperr & Karl Sotlar Peter Valent Karl Sotlar Tracy George Hans Peter Horny
14:00–15:00
SESSION 1: Updates in pathology and classification
• Harmonisation of the EU/US, ICC and WHO classificationof mastocytosis • Application of ICC and WHO criteria by the pathologist • Histopathological and phenotypic changes of mast cellsduring TKI therapy • Rare cases and histopathological patterns in SM-AHN
Chaired by Wolfgang R Sperr & Karl Sotlar Peter Valent Karl Sotlar Tracy George Hans Peter Horny
15:00–15:30
Afternoon coffee break
15:00–15:30
Afternoon coffee break
15:00–15:30
Afternoon coffee break
15:30–16:45
SESSION 2: Updates in paediatric and adult dermatological presentations of mast cell disease
• Diagnosis and management of skin problems in paediatricmastocytosis • Quantification of skin disease in CM and SM during therapy • Therapy of cutaneous disease in pediatric CM • Phototherapy and photochemotherapy in CM and SM • Challenges and potential shortfalls in current classificationof cutaneous mastocytosis
Chaired by Magdalena Lange & Vito Sabato Melody Carter Karin Hartmann Magdalena Lange Valeria Brazzelli & Iván Álvarez-Twose
15:30–16:45
SESSION 2: Updates in paediatric and adult dermatological presentations of mast cell disease
• Diagnosis and management of skin problems in paediatricmastocytosis • Quantification of skin disease in CM and SM during therapy • Therapy of cutaneous disease in pediatric CM • Phototherapy and photochemotherapy in CM and SM • Challenges and potential shortfalls in current classificationof cutaneous mastocytosis
Chaired by Magdalena Lange & Vito Sabato Melody Carter Karin Hartmann Magdalena Lange Valeria Brazzelli & Iván Álvarez-Twose
15:30–16:45
SESSION 2: Updates in paediatric and adult dermatological presentations of mast cell disease
• Diagnosis and management of skin problems in paediatricmastocytosis • Quantification of skin disease in CM and SM during therapy • Therapy of cutaneous disease in pediatric CM • Phototherapy and photochemotherapy in CM and SM • Challenges and potential shortfalls in current classificationof cutaneous mastocytosis
Chaired by Magdalena Lange & Vito Sabato Melody Carter Karin Hartmann Magdalena Lange Valeria Brazzelli & Iván Álvarez-Twose
16:45–17:15
Afternoon coffee break
16:45–17:15
Afternoon coffee break
16:45–17:15
Afternoon coffee break
17:15–18:15
SESSION 3: Comorbidities in mastocytosis
• Bone health and disease management in patients with SM • Drug reactions and food intolerance in mastocytosis • Causes of death in patients with mastocytosis: Impactof comorbidities • IgE-dependent allergies in mastocytosis
Chaired by Knut Brockow & Massimo Triggiani Massimo Triggiani Mariana Castells Axel Rüfer Hanneke Oude Elberink
17:15–18:15
SESSION 3: Comorbidities in mastocytosis
• Bone health and disease management in patients with SM • Drug reactions and food intolerance in mastocytosis • Causes of death in patients with mastocytosis: Impactof comorbidities • IgE-dependent allergies in mastocytosis
Chaired by Knut Brockow & Massimo Triggiani Massimo Triggiani Mariana Castells Axel Rüfer Hanneke Oude Elberink
17:15–18:15
SESSION 3: Comorbidities in mastocytosis
• Bone health and disease management in patients with SM • Drug reactions and food intolerance in mastocytosis • Causes of death in patients with mastocytosis: Impactof comorbidities • IgE-dependent allergies in mastocytosis
Chaired by Knut Brockow & Massimo Triggiani Massimo Triggiani Mariana Castells Axel Rüfer Hanneke Oude Elberink
18:15–18:55
Keynote lecture 1:
Mast cells and basophils in allergo-oncology: Bridging allergy to cancer
Introduced by Clive Grattan Sophia Karagiannis
18:15–18:55
Keynote lecture 1:
Mast cells and basophils in allergo-oncology: Bridging allergy to cancer
Introduced by Clive Grattan Sophia Karagiannis
18:15–18:55
Keynote lecture 1:
Mast cells and basophils in allergo-oncology: Bridging allergy to cancer
Introduced by Clive Grattan Sophia Karagiannis
18:55–19:00
Summary of Day 1 and announcements
18:55–19:00
Summary of Day 1 and announcements
18:55–19:00
Summary of Day 1 and announcements
19:30–20:30
19:30–20:30
19:30–20:30
Networking reception
Networking reception
Networking reception
Join fellow attendees, faculty, and colleagues for an
evening of informal networking, accompanied by drinks and light refreshments, in the elegant
Riverview Lounge overlooking the River Thames.
This reception offers a valuable opportunity to continue discussions from the day in a relaxed setting
and to connect with peers from across the field.
Riverview Lounge, 12th Floor
Park Plaza London Riverbank Hotel, London
Kindly register for this reception
by 31 August via the following link: www.surveymonkey.com/r/XPPX26T
Join fellow attendees, faculty, and colleagues for an
evening of informal networking, accompanied by drinks and light refreshments, in the elegant
Riverview Lounge overlooking the River Thames.
This reception offers a valuable opportunity to continue discussions from the day in a relaxed setting
and to connect with peers from across the field.
Riverview Lounge, 12th Floor
Park Plaza London Riverbank Hotel, London
Kindly register for this reception
by 31 August via the following link: www.surveymonkey.com/r/XPPX26T
Join fellow attendees, faculty, and colleagues for an
evening of informal networking, accompanied by drinks and light refreshments, in the elegant
Riverview Lounge overlooking the River Thames.
This reception offers a valuable opportunity to continue discussions from the day in a relaxed setting
and to connect with peers from across the field.
Riverview Lounge, 12th Floor
Park Plaza London Riverbank Hotel, London
Kindly register for this reception
by 31 August via the following link: www.surveymonkey.com/r/XPPX26T
Day 2, Friday 19
Day 2, Friday 19
Day 2, Friday 19
September 2025
September 2025
September 2025
08:30
Welcome and registration
08:30
Welcome and registration
08:30
Welcome and registration
09:00–10:00
SESSION 4: ECNM Registry projects – part 1
• Overview of ECNM registry projects • Highlights in W1 through W8 projects • PR1: Analysis of various age groups • PR14: Body mass index in mastocytosis • PR18: Pure CM in adults
Chaired by Wolfgang R Sperr & Michel Arock Wolfgang R. Sperr Peter Valent Karin Hartmann Marek Niedoszytko Knut Brockow
09:00–10:00
SESSION 4: ECNM Registry projects – part 1
• Overview of ECNM registry projects • Highlights in W1 through W8 projects • PR1: Analysis of various age groups • PR14: Body mass index in mastocytosis • PR18: Pure CM in adults
Chaired by Wolfgang R Sperr & Michel Arock Wolfgang R. Sperr Peter Valent Karin Hartmann Marek Niedoszytko Knut Brockow
09:00–10:00
SESSION 4: ECNM Registry projects – part 1
• Overview of ECNM registry projects • Highlights in W1 through W8 projects • PR1: Analysis of various age groups • PR14: Body mass index in mastocytosis • PR18: Pure CM in adults
Chaired by Wolfgang R Sperr & Michel Arock Wolfgang R. Sperr Peter Valent Karin Hartmann Marek Niedoszytko Knut Brockow
10:00–10:20
Morning coffee break
10:00–10:20
Morning coffee break
10:00–10:20
Morning coffee break
10:20–11:00
SESSION 4: ECNM Registry projects – part 2
• PR19: AHN: Frequency of subtypes and prognosis • PR42: Clinical impact of KITD816V VAF in SM • PR45: Causes of death in non-advanced SM • Overview of new projects and EU grant application
Chaired by Wolfgang R Sperr & Michel Arock Olivier Hermine Frank Siebenhaar Axel Rüfer & Theo Gülen Peter Valent
10:20–11:00
SESSION 4: ECNM Registry projects – part 2
• PR19: AHN: Frequency of subtypes and prognosis • PR42: Clinical impact of KITD816V VAF in SM • PR45: Causes of death in non-advanced SM • Overview of new projects and EU grant application
Chaired by Wolfgang R Sperr & Michel Arock Olivier Hermine Frank Siebenhaar Axel Rüfer & Theo Gülen Peter Valent
10:20–11:00
SESSION 4: ECNM Registry projects – part 2
• PR19: AHN: Frequency of subtypes and prognosis • PR42: Clinical impact of KITD816V VAF in SM • PR45: Causes of death in non-advanced SM • Overview of new projects and EU grant application
Chaired by Wolfgang R Sperr & Michel Arock Olivier Hermine Frank Siebenhaar Axel Rüfer & Theo Gülen Peter Valent
11:00–11:15
Morning coffee break
11:00–11:15
Morning coffee break
11:00–11:15
Morning coffee break
11:15–12:00
SESSION SATELLITE MEETING – CLINICAL SCENARIOS
11:15–12:00
SESSION SATELLITE MEETING – CLINICAL SCENARIOS
11:15–12:00
SESSION SATELLITE MEETING – CLINICAL SCENARIOS
12:50–13:00
Group photo
12:50–13:00
Group photo
12:50–13:00
Group photo
13:00–13:45
Keynote lecture 2:
Molecular studies in mastocytosis and AHN, and use of AI tools
Introduced by Peter Valent Gregor Hörmann
13:00–13:45
Keynote lecture 2:
Molecular studies in mastocytosis and AHN, and use of AI tools
Introduced by Peter Valent Gregor Hörmann
13:00–13:45
Keynote lecture 2:
Molecular studies in mastocytosis and AHN, and use of AI tools
Introduced by Peter Valent Gregor Hörmann
13:45–15:00
SESSION 5: Diagnostic challenges in mastocytosis
• Lab features and flow cytometry correlates with clinicalphenotypes • I think I have the mast cell • HαT and implications in clinical practice • Early phases and pre-phases of mast cell neoplasms • Classification of pre-SM conditions and developmentof prevention strategies
Chaired by Iván Álvarez-Twose & Karin Hartmann Alberto Orfao Clive Grattan Jonathan Lyons Olivier Hermine Peter Valent
13:45–15:00
SESSION 5: Diagnostic challenges in mastocytosis
• Lab features and flow cytometry correlates with clinicalphenotypes • I think I have the mast cell • HαT and implications in clinical practice • Early phases and pre-phases of mast cell neoplasms • Classification of pre-SM conditions and developmentof prevention strategies
Chaired by Iván Álvarez-Twose & Karin Hartmann Alberto Orfao Clive Grattan Jonathan Lyons Olivier Hermine Peter Valent
13:45–15:00
SESSION 5: Diagnostic challenges in mastocytosis
• Lab features and flow cytometry correlates with clinicalphenotypes • I think I have the mast cell • HαT and implications in clinical practice • Early phases and pre-phases of mast cell neoplasms • Classification of pre-SM conditions and developmentof prevention strategies
Chaired by Iván Álvarez-Twose & Karin Hartmann Alberto Orfao Clive Grattan Jonathan Lyons Olivier Hermine Peter Valent
15:00–15:25
Afternoon coffee break
15:00–15:25
Afternoon coffee break
15:00–15:25
Afternoon coffee break
15:25–16:40
SESSION 6: Anaphylaxis and mast cell activation syndrome
• Why we have mast cells: The venom interception theory • How to manage false-positive MCAS and its mimickers • Diagnosis and management of MCAS • Immunotherapy in mastocytosis • Long- or short-term Hymenoptera venom immunotherapyin mastocytosis?
Chaired by Jens Peter Panse & Hanneke Oude Elberink Stephen Galli Theo Gulen Cem Akin Marek Niedoszytko Patrizia Bonadonna
15:25–16:40
SESSION 6: Anaphylaxis and mast cell activation syndrome
• Why we have mast cells: The venom interception theory • How to manage false-positive MCAS and its mimickers • Diagnosis and management of MCAS • Immunotherapy in mastocytosis • Long- or short-term Hymenoptera venom immunotherapyin mastocytosis?
Chaired by Jens Peter Panse & Hanneke Oude Elberink Stephen Galli Theo Gulen Cem Akin Marek Niedoszytko Patrizia Bonadonna
15:25–16:40
SESSION 6: Anaphylaxis and mast cell activation syndrome
• Why we have mast cells: The venom interception theory • How to manage false-positive MCAS and its mimickers • Diagnosis and management of MCAS • Immunotherapy in mastocytosis • Long- or short-term Hymenoptera venom immunotherapyin mastocytosis?
Chaired by Jens Peter Panse & Hanneke Oude Elberink Stephen Galli Theo Gulen Cem Akin Marek Niedoszytko Patrizia Bonadonna
16:40–17:10
Afternoon coffee break
16:40–17:10
Afternoon coffee break
16:40–17:10
Afternoon coffee break
17:10–18:25
SESSION 7: Translational and real-world research in mastocytosis
• Which biomarkers are useful in mast cell activation? • Detection of KIT variants in blood and skin of patients with mastocytosis • Tryptase: From bench to clinical use in applied haematology • Biology of tryptase and application in practice • Tryptase as a screening parameter in paediatric mastocytosis
Chaired by Sigurd Broesby-Olsen & Marek Niedoszytko Gunnar Nilsson Sigurd Broesby-Olsen Wolfgang R. Sperr Lawrence B. Schwartz Knut Brockow
17:10–18:25
SESSION 7: Translational and real-world research in mastocytosis
• Which biomarkers are useful in mast cell activation? • Detection of KIT variants in blood and skin of patients with mastocytosis • Tryptase: From bench to clinical use in applied haematology • Biology of tryptase and application in practice • Tryptase as a screening parameter in paediatric mastocytosis
Chaired by Sigurd Broesby-Olsen & Marek Niedoszytko Gunnar Nilsson Sigurd Broesby-Olsen Wolfgang R. Sperr Lawrence B. Schwartz Knut Brockow
17:10–18:25
SESSION 7: Translational and real-world research in mastocytosis
• Which biomarkers are useful in mast cell activation? • Detection of KIT variants in blood and skin of patients with mastocytosis • Tryptase: From bench to clinical use in applied haematology • Biology of tryptase and application in practice • Tryptase as a screening parameter in paediatric mastocytosis
Chaired by Sigurd Broesby-Olsen & Marek Niedoszytko Gunnar Nilsson Sigurd Broesby-Olsen Wolfgang R. Sperr Lawrence B. Schwartz Knut Brockow
18:25–18:30
Summary of Day 2 and announcements
18:25–18:30
Summary of Day 2 and announcements
18:25–18:30
Summary of Day 2 and announcements
19:00–22:00
19:00–22:00
19:00–22:00
Networking dinner
Networking dinner
Networking dinner
Join colleagues, faculty, and peers for a formal seated dinner in a distinguished setting, offering the perfect opportunity to unwind after a full day of engaging scientific discussions.
Enjoy an elegant evening of fine dining and conversation in the company of leading experts from across the field.
Dinner at Merchant Taylors’ Hall, City of London
Kindly register for this dinner by 31 August via the following link: www.surveymonkey.com/r/3YZDHTL
Join colleagues, faculty, and peers for a formal seated dinner in a distinguished setting, offering the perfect opportunity to unwind after a full day of engaging scientific discussions.
Enjoy an elegant evening of fine dining and conversation in the company of leading experts from across the field.
Dinner at Merchant Taylors’ Hall, City of London
Kindly register for this dinner by 31 August via the following link: www.surveymonkey.com/r/3YZDHTL
Join colleagues, faculty, and peers for a formal seated dinner in a distinguished setting, offering the perfect opportunity to unwind after a full day of engaging scientific discussions.
Enjoy an elegant evening of fine dining and conversation in the company of leading experts from across the field.
Dinner at Merchant Taylors’ Hall, City of London
Kindly register for this dinner by 31 August via the following link: www.surveymonkey.com/r/3YZDHTL
Day 3, Saturday 20
Day 3, Saturday 20
Day 3, Saturday 20
September 2025
September 2025
September 2025
08:00
Welcome and registration
08:00
Welcome and registration
08:00
Welcome and registration
08:30–09:30
SESSION 8: Prognostication and efficacy of novel TKIs in SM
• Development of MARS-R • Efficacy of recently approved and novel TKIs in SM clinicalpractice • Real-world data of avapritinib-treated patients with ISM • Diagnosis, prognostication and therapy of WDSM
Chaired by Tracy George & Juliana Schwaab Johannes Lübke Juliana Schwaab Frank Siebenhaar Iván Álvarez-Twose
08:30–09:30
SESSION 8: Prognostication and efficacy of novel TKIs in SM
• Development of MARS-R • Efficacy of recently approved and novel TKIs in SM clinicalpractice • Real-world data of avapritinib-treated patients with ISM • Diagnosis, prognostication and therapy of WDSM
Chaired by Tracy George & Juliana Schwaab Johannes Lübke Juliana Schwaab Frank Siebenhaar Iván Álvarez-Twose
08:30–09:30
SESSION 8: Prognostication and efficacy of novel TKIs in SM
• Development of MARS-R • Efficacy of recently approved and novel TKIs in SM clinicalpractice • Real-world data of avapritinib-treated patients with ISM • Diagnosis, prognostication and therapy of WDSM
Chaired by Tracy George & Juliana Schwaab Johannes Lübke Juliana Schwaab Frank Siebenhaar Iván Álvarez-Twose
09:30–10:00
Morning coffee break
09:30–10:00
Morning coffee break
09:30–10:00
Morning coffee break
10:00–12:00
SESSION 9: Invited presentations and late-breaking abstracts
Chaired by Deepti Radia & Jason Gotlib
10:00–12:00
SESSION 9: Invited presentations and late-breaking abstracts
Chaired by Deepti Radia & Jason Gotlib
10:00–12:00
SESSION 9: Invited presentations and late-breaking abstracts
Chaired by Deepti Radia & Jason Gotlib
12:00–13:00
Lunch break and poster sessions
12:00–13:00
Lunch break and poster sessions
12:00–13:00
Lunch break and poster sessions
13:00–14:15
SESSION 10: Updates in management of advanced and non-advanced systemic mastocytosis – looking forwards
• Non-advanced SM landscape: TKIs • Non-advanced SM landscape: Non-TKIs • Mutational landscape changing the paradigm for treatment • Advanced SM landscape and complete remission and cure: The new goal in patients with advanced SM: Status 2025 • Role of allogeneic BMT
Chaired by Frank Siebenhaar & Peter Valent Cem Akin Vito Sabato Andreas Reiter Jason Gotlib Deepti Radia
13:00–14:15
SESSION 10: Updates in management of advanced and non-advanced systemic mastocytosis – looking forwards
• Non-advanced SM landscape: TKIs • Non-advanced SM landscape: Non-TKIs • Mutational landscape changing the paradigm for treatment • Advanced SM landscape and complete remission and cure: The new goal in patients with advanced SM: Status 2025 • Role of allogeneic BMT
Chaired by Frank Siebenhaar & Peter Valent Cem Akin Vito Sabato Andreas Reiter Jason Gotlib Deepti Radia
13:00–14:15
SESSION 10: Updates in management of advanced and non-advanced systemic mastocytosis – looking forwards
• Non-advanced SM landscape: TKIs • Non-advanced SM landscape: Non-TKIs • Mutational landscape changing the paradigm for treatment • Advanced SM landscape and complete remission and cure: The new goal in patients with advanced SM: Status 2025 • Role of allogeneic BMT
Chaired by Frank Siebenhaar & Peter Valent Cem Akin Vito Sabato Andreas Reiter Jason Gotlib Deepti Radia
14:15–14:30
Summary of Day 3 and closing remarks
Peter Valent Massimo Triggiani Deepti Radia Clive Grattan
14:15–14:30
Summary of Day 3 and closing remarks
Peter Valent Massimo Triggiani Deepti Radia Clive Grattan
14:15–14:30
Summary of Day 3 and closing remarks
Peter Valent Massimo Triggiani Deepti Radia Clive Grattan